Friday | 5 December, 2008
Australian Biotechnology News

Stories about: Sharp

  • +

    Two advance to BIO 26/03/2008 16:16:11

    Two local scientists are off to the BIO convention in June after winning the Advance BioBusiness award.
  • +

    Bring on the debate 17/01/2008 16:09:10

    New science minister promises charters of independence for public researchers.
  • +

    Advance to San Diego 30/10/2007 12:31:42

    Applications are open for the second Advancing BioBusiness Award.
  • +

    AusBiotech special: Australia's place in the global gravity shift 15/10/2007 16:09:48

    With AusBiotech 2007 being held in Brisbane next week, ALS takes its bi-annual survey of the state of the industry.
  • +

    Kiwi uni buys into Blue Gene 04/06/2007 14:31:17

    New Zealand's University of Canterbury will be the first research institution in the southern hemisphere to have an IBM Blue Gene supercomputer.
  • +

    BioBusiness winners advance to Boston 02/05/2007 10:33:15

    Biota and Cytopia leaders win Advancing BioBusiness award
  • +

    Pre-stained protein standards 26/04/2007 10:00:05

    The Novex Sharp Protein Standard provides bands in a pre-stained format for various protein gel electrophoresis applications.
  • +

    FEI takes quanta leap 25/04/2007 11:15:53

    FEI has released an analytical DualBeam for advanced 3D R&D.
  • +

    Doing business with the big boys 15/11/2006 15:43:16

    So, you're a small biotech looking to get into bed with Big Pharma. Kate McDonald spoke to Merck's head of research Ismail Kola about life on the dark side.
  • +

    Biotech performance was tale of two halves in 2005: Intersuisse 11/01/2006 11:14:02

    Australian biotech stocks underperformed both the All Ordinaries and the Nasdaq Biotech Index in 2005, but the second half of the year was brighter with stocks gaining 23.2 per cent, according to the Intersuisse Biotechnology Index.
  • +

    C3 surprised by TGA thumbs-down for ReCell 21/12/2005 12:43:58

    Tissue engineering specialist Clinical Cell Culture's (ASX:CCE, C3) share price dropped by nearly 30 per cent today on news that the Therapeutic Goods Administration (TGA) intends to reject approval for its ReCell product in Australia.
Additional Resources
Newsletter Subscription
Sign up for our Australian Life Scientist newsletters!
 
Sponsored Links